Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
9.843
Zitationen
8
Autoren
2011
Jahr
Abstract
PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument's sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording 'slight-moderate-severe' problems, with anchors of 'no problems' and 'unable to do' in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects.
Ähnliche Arbeiten
Meta-analysis in clinical trials
1986 · 39.000 Zit.
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
2018 · 38.595 Zit.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 · 37.710 Zit.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 · 33.826 Zit.
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · 29.409 Zit.
Autoren
Institutionen
- Gavekal Intelligence Software (France)(FR)
- Municipal Institute for Medical Research(ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública(ES)
- Odense University Hospital(DK)
- Health Economics and Outcomes Research (United Kingdom)(GB)
- EuroQol Research Foundation(NL)
- University of York(GB)
- East Sussex Healthcare NHS Trust(GB)
- Erasmus MC(NL)